Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes self‐harm Timing of outcome assessment: end of treatment (8 to 24… compared with placebo (very low certainty).
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Mood stabilisers may leads to lower attrition Timing of outcome assessment: end of treatment (32 days to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Deliberate self‐harm · patients with borderline personality disorder
1 finding from 1 review
Intervention not reported
Knowledge and understanding Variable scales: information (amount and type) needs/preferences; discordance between patient and physician survival and curability estimates Timing: immediately to 1 month post‐consultation · people approaching the end of life (within 12 months), their family members and/or carers
1 finding from 1 review
Intervention not reported
Evaluation of the communication: different constructs (perceptions of communication quality; patient‐centredness of communication; involvement preferences; doctor‐patient relationship measures) Timing: immediately post‐consultation to 18 weeks pos... · people approaching the end of life (within 12 months), their family members and/or carers
1 finding from 1 review
Intervention not reported
Discussions of EoL/EoL care: discussion timing and length EMR review post‐death Timing: at time of family conference (intervention) in ICU; post‐death  · people approaching the end of life (within 12 months), their family members and/or carers
1 finding from 1 review
Intervention not reported
Discussions of EoL/EoL care: discussion occurrence EMR review post‐death; coding of consultations; self‐reported occurrence Timing: immediately, 1 or 2 weeks post‐consultation; after death · people approaching the end of life (within 12 months), their family members and/or carers
1 finding from 1 review
Intervention not reported
Adverse (unintended) outcomes  · people approaching the end of life (within 12 months), their family members and/or carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found